Hmm..
"
On 28 October 2013, Invion announced it had entered a licence agreement with Accolade Pharma LLC for an exclusive, worldwide licence to develop and commercialise all inhaled formulations and applications of zafirlukast. A licence fee of $500,000 was payable by Invion to Accolade Pharma LLC over a 12 month period commencing January 2014. Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC. "
- Forums
- ASX - By Stock
- IVX
- Ann: Notice under Section 708A
Ann: Notice under Section 708A, page-18
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IVX (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $26.55M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $13.29K | 3.468M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 6373939 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 5595292 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11033 | 0.004 |
8 | 6840606 | 0.003 |
26 | 31544015 | 0.002 |
18 | 20233817 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 5000 | 1 |
0.004 | 5081196 | 10 |
0.005 | 8538292 | 25 |
0.006 | 3176372 | 11 |
0.007 | 3352309 | 6 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
IVX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online